{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:55:53Z","timestamp":1795110953419,"version":"4.10.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["No.2023YFF1204700, branch No.2023YFF1204702"],"award-info":[{"award-number":["No.2023YFF1204700, branch No.2023YFF1204702"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15442-9","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:26:16Z","timestamp":1765358776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The value of translational therapy in the treatment of advanced hepatoid adenocarcinoma of stomach"],"prefix":"10.1186","volume":"26","author":[{"given":"Liqiao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaode","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"3","key":"15442_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"key":"15442_CR2","doi-asserted-by":"publisher","first-page":"103841","DOI":"10.1016\/j.critrevonc.2022.103841","volume":"181","author":"MJ L\u00f3pez","year":"2023","unstructured":"L\u00f3pez MJ, Carbajal J, Alfaro AL, Saravia LG, Zanabria D, Araujo JM, et al. Characteristics of gastric cancer around the world. Crit Rev Oncol Hematol. 2023;181:103841.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"15442_CR3","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s10120-019-00965-5","volume":"22","author":"Y Wang","year":"2019","unstructured":"Wang Y, Sun L, Li Z, Gao J, Ge S, Zhang C, et al. Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. Gastric Cancer. 2019;22(6):1183\u201392.","journal-title":"Gastric Cancer"},{"issue":"16","key":"15442_CR4","doi-asserted-by":"publisher","first-page":"e70130","DOI":"10.1002\/cam4.70130","volume":"13","author":"Q Ling","year":"2024","unstructured":"Ling Q, Liu H-L, Huang S-T, Sun L-F, Wu W-W, Kudriashov V, et al. Clinicopathological features of hepatoid adenocarcinoma and non-hepatoid adenocarcinoma of the stomach: A systematic review and meta-analysis. Cancer Med. 2024;13(16):e70130.","journal-title":"Cancer Med"},{"issue":"38","key":"15442_CR5","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1038\/s41388-021-01976-2","volume":"40","author":"Z Liu","year":"2021","unstructured":"Liu Z, Wang A, Pu Y, Li Z, Xue R, Zhang C, et al. Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach. Oncogene. 2021;40(38):5705\u201317.","journal-title":"Oncogene"},{"issue":"15","key":"15442_CR6","doi-asserted-by":"publisher","first-page":"e3399","DOI":"10.1097\/MD.0000000000003399","volume":"95","author":"BG Qu","year":"2016","unstructured":"Qu BG, Bi WM, Qu BT, Qu T, Han XH, Wang H, et al.PRISMA-Compliant article: clinical characteristics and factors influencing prognosis of patients with hepatoid adenocarcinoma of the stomach in China. Med (Baltim). 2016;95(15):e3399.","journal-title":"Med (Baltim)"},{"issue":"1","key":"15442_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2050-7771-1-32","volume":"1","author":"M-Z Qiu","year":"2013","unstructured":"Qiu M-Z, Xu R-H. The progress of targeted therapy in advanced gastric cancer. Biomark Res. 2013;1(1):32.","journal-title":"Biomark Res"},{"key":"15442_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40164-019-0149-6","volume":"8","author":"JH Selim","year":"2019","unstructured":"Selim JH, Shaheen S, Sheu WC, Hsueh CT. Targeted and novel therapy in advanced gastric cancer. Exp Hematol Oncol. 2019;8:25.","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"15442_CR9","first-page":"Cd004064","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):Cd004064.","journal-title":"Cochrane Database Syst Rev"},{"key":"15442_CR10","doi-asserted-by":"publisher","first-page":"948647","DOI":"10.3389\/fimmu.2022.948647","volume":"13","author":"X Jin","year":"2022","unstructured":"Jin X, Liu Z, Yang D, Yin K, Chang X. Recent progress and future perspectives of immunotherapy in advanced gastric cancer. Front Immunol. 2022;13:948647.","journal-title":"Front Immunol"},{"key":"15442_CR11","first-page":"2162229","volume":"2022","author":"X Xu","year":"2022","unstructured":"Xu X, Li J, Gao Y, Lv W, Wei Q, Tang X, et al. Associations of clinical and molecular characteristics with the response to immune checkpoint Blockade in advanced gastric cancers. J Oncol. 2022;2022:2162229.","journal-title":"J Oncol"},{"issue":"8","key":"15442_CR12","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/annonc\/mdx051","volume":"28","author":"F Lordick","year":"2017","unstructured":"Lordick F, Shitara K, Janjigian YY. New agents on the horizon in gastric cancer. Ann Oncol. 2017;28(8):1767\u201375.","journal-title":"Ann Oncol"},{"key":"15442_CR13","doi-asserted-by":"publisher","first-page":"175883592412661","DOI":"10.1177\/17588359241266156","volume":"16","author":"P He","year":"2024","unstructured":"He P, Ma L, Xu B, Wang Y, Li X, Chen H, Li Y. Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer. Ther Adv Med Oncol. 2024;16:17588359241266156.","journal-title":"Ther Adv Med Oncol"},{"key":"15442_CR14","doi-asserted-by":"crossref","unstructured":"Pinto MP, C\u00f3rdova-Delgado M, Retamal IN, Mu\u00f1oz-Medel M, Bravo ML, Dur\u00e1n D, et al. A molecular stratification of Chilean gastric cancer patients with potential clinical applicability. Cancers (Basel) 2020, 12(7).","DOI":"10.3390\/cancers12071863"},{"issue":"6","key":"15442_CR15","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/1097-0142(19930915)72:6<1827::AID-CNCR2820720606>3.0.CO;2-8","volume":"72","author":"E Nagai","year":"1993","unstructured":"Nagai E, Ueyama T, Yao T, Tsuneyoshi M. Hepatoid adenocarcinoma of the stomach. A clinicopathologic and immunohistochemical analysis. Cancer. 1993;72(6):1827\u201335.","journal-title":"Cancer"},{"issue":"1","key":"15442_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12885-023-10516-y","volume":"23","author":"X Yang","year":"2023","unstructured":"Yang X, Wang A, Li J, Zhou K, Ji K, Ji X, et al. Prognostic significance of preoperative serum tumor markers in hepatoid adenocarcinoma of stomach (HAS). BMC Cancer. 2023;23(1):53.","journal-title":"BMC Cancer"},{"key":"15442_CR17","doi-asserted-by":"publisher","first-page":"216104","DOI":"10.1016\/j.canlet.2023.216104","volume":"559","author":"M Li","year":"2023","unstructured":"Li M, Mei Y-X, Wen J-H, Jiao Y-R, Pan Q-R, Kong X-X, Li J. Hepatoid adenocarcinoma-Clinicopathological features and molecular characteristics. Cancer Lett. 2023;559:216104.","journal-title":"Cancer Lett"},{"key":"15442_CR18","doi-asserted-by":"publisher","first-page":"633916","DOI":"10.3389\/fonc.2021.633916","volume":"11","author":"R Xia","year":"2021","unstructured":"Xia R, Zhou Y, Wang Y, Yuan J, Ma X. Hepatoid adenocarcinoma of the stomach: current perspectives and new developments. Front Oncol. 2021;11:633916.","journal-title":"Front Oncol"},{"issue":"3","key":"15442_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10120-016-0633-1","volume":"20","author":"Y Sato","year":"2017","unstructured":"Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, et al. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer. 2017;20(3):517\u201326.","journal-title":"Gastric Cancer"},{"key":"15442_CR20","doi-asserted-by":"publisher","first-page":"642511","DOI":"10.3389\/fphar.2021.642511","volume":"12","author":"Z Xu","year":"2021","unstructured":"Xu Z, Hu C, Yu J, Du Y, Hu P, Yu G, et al. Efficacy of conversion surgery following apatinib plus Paclitaxel\/S1 for advanced gastric cancer with unresectable factors: A Multicenter, Single-Arm, phase II trial. Front Pharmacol. 2021;12:642511.","journal-title":"Front Pharmacol"},{"issue":"10","key":"15442_CR21","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ijsu.2014.08.349","volume":"12","author":"S Hashemzadeh","year":"2014","unstructured":"Hashemzadeh S, Pourzand A, Somi MH, Zarrintan S, Javad-Rashid R, Esfahani A. The effects of neoadjuvant chemotherapy on resectability of locally-advanced gastric adenocarcinoma: a clinical trial. Int J Surg. 2014;12(10):1061\u20139.","journal-title":"Int J Surg"},{"key":"15442_CR22","doi-asserted-by":"publisher","first-page":"1496342","DOI":"10.3389\/fimmu.2024.1496342","volume":"15","author":"L Li","year":"2024","unstructured":"Li L, Zhang D, Zhu J, Zhang G. Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report. Front Immunol. 2024;15:1496342.","journal-title":"Front Immunol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15442-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15442-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15442-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T14:25:23Z","timestamp":1769437523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15442-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15442"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15442-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study of human data was performed according to the Declaration of Helsinki and Good Clinical Practice. The protocol of this research and the license for usage of clinical data were given by the Ethics Committee of Peking University Cancer Hospital and Institute (code PY202329). All patients were informed and signed the informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}